{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:06:44Z","timestamp":1791446804140,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/13\/48\/3045"],"award-info":[{"award-number":["FS\/13\/48\/3045"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0800318"],"award-info":[{"award-number":["G0800318"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/08\/061\/25740"],"award-info":[{"award-number":["FS\/08\/061\/25740"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health Research Sheffield Cardiovascular Biomedical Research Unit"},{"name":"Cambridge National Institute of Health Research Biomedical Research Centre"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.vph.2014.10.002","type":"journal-article","created":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T10:43:27Z","timestamp":1413629007000},"page":"114-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of the osteoprotegerin\/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension"],"prefix":"10.1016","volume":"63","author":[{"given":"Allan","family":"Lawrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2014.10.002_bb0005","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and Diagnosis of Pulmonary Hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"Jac"},{"key":"10.1016\/j.vph.2014.10.002_bb0010","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated Clinical Classification of Pulmonary Hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"Jac"},{"key":"10.1016\/j.vph.2014.10.002_bb0015","series-title":"2012 National Audit of Pulmonary Hypertension","author":"NHS","year":"2014"},{"key":"10.1016\/j.vph.2014.10.002_bb0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vph.2014.10.002_bb0025","doi-asserted-by":"crossref","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","article-title":"Relevant issues in the pathology and pathobiology of pulmonary hypertension","volume":"62","author":"Tuder","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.10.002_bb0030","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2014.10.002_bb0035","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1183\/09031936.00078411","article-title":"ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre","volume":"39","author":"Hurdman","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vph.2014.10.002_bb0040","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1172\/JCI33452","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"118","author":"Rabinovitch","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2014.10.002_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.vph.2014.10.002_bb0050","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","volume":"111","author":"Petkov","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2014.10.002_bb0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00380-009-1176-8","article-title":"Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension","volume":"25","author":"Fujita","year":"2010","journal-title":"Heart Vessels"},{"key":"10.1016\/j.vph.2014.10.002_bb0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vph.2014.10.002_bb0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/2045-8932.87299","article-title":"Apelin and pulmonary hypertension","volume":"1","author":"Andersen","year":"2011","journal-title":"Pulm Circ"},{"key":"10.1016\/j.vph.2014.10.002_bb0070","doi-asserted-by":"crossref","first-page":"720305","DOI":"10.1155\/2010\/720305","article-title":"Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension","volume":"2010","author":"Furuya","year":"2010","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.vph.2014.10.002_bb0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200811-1682OC","article-title":"Role of epidermal growth factor inhibition in experimental pulmonary hypertension","volume":"181","author":"Dahal","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vph.2014.10.002_bb0080","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/CIRCULATIONAHA.105.540542","article-title":"Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension","volume":"112","author":"Merklinger","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.10.002_bb0085","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/CIRCULATIONAHA.106.663120","article-title":"Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation","volume":"115","author":"Hansmann","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.10.002_bb0090","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00210-013-0846-3","article-title":"Relaxation of human pulmonary arteries by PPAR\u03b3 agonists","volume":"386","author":"Koz\u0142owska","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.vph.2014.10.002_bb0095","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cvr\/cvt341","article-title":"Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity","volume":"101","author":"Kelley","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vph.2014.10.002_bb0100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.vph.2014.10.002_bb0105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.lfs.2011.09.003","article-title":"Novel transcript variants of TRAIL show different activities in activation of NF-\u03baB and apoptosis","volume":"89","author":"Wang","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.vph.2014.10.002_bb0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.vph.2014.10.002_bb0115","doi-asserted-by":"crossref","first-page":"25417","DOI":"10.1074\/jbc.272.41.25417","article-title":"Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL","volume":"272","author":"MacFarlane","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.10.002_bb0120","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","article-title":"TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL","volume":"16","author":"Walczak","year":"1997","journal-title":"Embo J"},{"key":"10.1016\/j.vph.2014.10.002_bb0125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0960-9822(06)00297-1","article-title":"TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL","volume":"7","author":"Screaton","year":"1997","journal-title":"Curr Biol"},{"key":"10.1016\/j.vph.2014.10.002_bb0130","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","article-title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL","volume":"277","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.vph.2014.10.002_bb0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1084\/jem.186.7.1165","article-title":"Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family","volume":"186","author":"DegliEsposti","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.vph.2014.10.002_bb0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.vph.2014.10.002_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-5793(98)00135-5","article-title":"TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling","volume":"424","author":"Pan","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vph.2014.10.002_bb0150","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0960-9822(06)00422-2","article-title":"A novel receptor for Apo2L\/TRAIL contains a truncated death domain","volume":"7","author":"Marsters","year":"1997","journal-title":"Curr Biol"},{"key":"10.1016\/j.vph.2014.10.002_bb0155","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1074-7613(00)80399-4","article-title":"The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain","volume":"7","author":"Degli-Esposti","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.vph.2014.10.002_bb0160","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.10.002_bb0165","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","article-title":"Death receptors: signaling and modulation","volume":"281","author":"Ashkenazi","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.vph.2014.10.002_bb0170","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2249.2004.02534.x","article-title":"Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells","volume":"137","author":"Miyashita","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vph.2014.10.002_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2009.02.029","article-title":"TRAIL as a target in anti-cancer therapy","volume":"285","author":"Wu","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.vph.2014.10.002_bb0180","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.10.002_bb0185","first-page":"3513","article-title":"Rare loss-of-function mutation of a death receptor gene in head and neck cancer","volume":"58","author":"Pai","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.vph.2014.10.002_bb0190","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.cdd.4401157","article-title":"Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation","volume":"10","author":"Hopkins-Donaldson","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.vph.2014.10.002_bb0195","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1042\/CS20050175","article-title":"Role of osteoprotegerin (OPG) in cancer","volume":"110","author":"Holen","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.vph.2014.10.002_bb0200","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1158\/1078-0432.CCR-07-5019","article-title":"OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer","volume":"14","author":"de Toni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vph.2014.10.002_bb0205","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1084\/jem.20122235","article-title":"TRAIL: not just for tumors anymore?","volume":"209","author":"Benedict","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.vph.2014.10.002_bb0210","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1189\/jlb.0211062","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation","volume":"90","author":"McGrath","year":"2011","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vph.2014.10.002_bb0215","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/thoraxjnl-2011-200863","article-title":"Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis","volume":"67","author":"McGrath","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.vph.2014.10.002_bb0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2567.2009.03058.x","article-title":"Following TRAIL's path in the immune system","volume":"127","author":"Falschlehner","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.vph.2014.10.002_bb0225","doi-asserted-by":"crossref","first-page":"L1045","DOI":"10.1152\/ajplung.2000.278.5.L1045","article-title":"TRAIL expression in vascular smooth muscle","volume":"278","author":"Gochuico","year":"2000","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.vph.2014.10.002_bb0230","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2353\/ajpath.2008.070395","article-title":"Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension","volume":"172","author":"Lawrie","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vph.2014.10.002_bb0235","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.ajpath.2011.06.037","article-title":"Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner","volume":"179","author":"Lawrie","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vph.2014.10.002_bb0240","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1074\/jbc.M706927200","article-title":"TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF- B and Induction of Insulin-like Growth Factor-1 Receptor","volume":"283","author":"Kavurma","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.10.002_bb0245","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00018-004-4197-6","article-title":"TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells","volume":"61","author":"Secchiero","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vph.2014.10.002_bb0250","article-title":"TRAIL Promotes VSMC Proliferation and Neointima Formation in a FGF-2-, Sp1 Phosphorylation-, and NF B-Dependent Manner","volume":"1\u201311","author":"Chan","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2014.10.002_bb0255","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2011.01.010","article-title":"TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice","volume":"215","author":"Watt","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.10.002_bb0260","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1161\/CIRCRESAHA.108.183285","article-title":"TRAIL\/Apo2L Mediates the Release of Procoagulant Endothelial Microparticles Induced by Thrombin In Vitro: A Potential Mechanism Linking Inflammation and Coagulation","volume":"104","author":"Simoncini","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2014.10.002_bb0265","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1084\/jem.20112716","article-title":"Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension","volume":"209","author":"Hameed","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.vph.2014.10.002_bb0270","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/diseases2030260","article-title":"TRAIL Deficient Mice Are Protected from Sugen\/Hypoxia Induced Pulmonary Arterial Hypertension","volume":"2","author":"Dawson","year":"2014","journal-title":"Diseases"},{"key":"10.1016\/j.vph.2014.10.002_bb0275","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T","article-title":"Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage","volume":"28","author":"Mariani","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vph.2014.10.002_bb0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.physiol.59.1.63","article-title":"Emerging roles for cysteine proteases in human biology","volume":"59","author":"Chapman","year":"1997","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.vph.2014.10.002_bb0285","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1172\/JCI57734","article-title":"Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease","volume":"121","author":"Ma","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2014.10.002_bb0290","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.vph.2014.10.002_bb0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.vph.2014.10.002_bb0300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/2045-8932.94819","article-title":"Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension","volume":"2","author":"Condliffe","year":"2012","journal-title":"Pulm Circ"},{"key":"10.1016\/j.vph.2014.10.002_bb0305","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.2491","article-title":"Potential pathogenic role of soluble receptor activator of nuclear factor-\u03baB ligand and osteoprotegerin in patients with pulmonary arterial hypertension","author":"Jasiewicz","year":"2014","journal-title":"Pol Arch Med Wewn"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T06:20:01Z","timestamp":1746426001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189114001657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1537189114001657"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.10.002","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the osteoprotegerin\/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}